Access and real-world use patterns of esketamine nasal spray among patients with treatment-resistant depression covered by private or public insurance-Reference-Cited by-同舟云学术

Access and real-world use patterns of esketamine nasal spray among patients with treatment-resistant depression covered by private or public insurance

Published:2023-08-03 Issue:8 Volume:39 Page:1167-1174
ISSN:0300-7995
Container-title:Current Medical Research and Opinion
language:en
Short-container-title:Current Medical Research and Opinion

Author:

Teeple Amanda¹,Zhdanava Maryia²,Pilon Dominic²,Caron-Lapointe Gabrielle²,Lefebvre Patrick²,Joshi Kruti¹

Affiliation:

1. US Real-World Value and Evidence, Janssen Scientific Affairs, LLC, Titusville, NJ, USA

2. Analysis Group, Inc, Montréal, QC, Canada

Publisher

Informa UK Limited

Subject

General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/03007995.2023.2239045

Reference30 articles.

1. Substance Abuse and Mental Health Services Administration. Key substance use and mental health indicators in the United States: results from the 2020 national survey on drug use and health (HHS Publication No. PEP21-07-01-003, NSDUH series H-56). Rockville (MD): Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration; 2021.

2. Major depressive disorder

3. Mayo Clinic. Depression (major depressive disorder); [cited 2020 Mar 18]. Available from: https://www.mayoclinic.org/diseases-conditions/depression/symptoms-causes/syc-20356007

4. World Health Organization. Depression; [cited 2020 Mar 18]. Available from: https://www.who.int/news-room/fact-sheets/detail/depression

5. Acute and Longer-Term Outcomes in Depressed Outpatients Requiring One or Several Treatment Steps: A STAR*D Report

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Understanding profiles of patients with treatment-resistant depression by stringency of health plan prior authorization criteria for approval of esketamine nasal spray;Current Medical Research and Opinion;2024-07-24

2. Efficacy of Esketamine among patients with treatment resistant depression in a ‘real world' health-care setting in Israel;Journal of Psychiatric Research;2024-06

3. Treatment Patterns, Acute Healthcare Resource Use, and Costs of Patients with Treatment-Resistant Depression Completing Induction Phase of Esketamine in the United States;Drugs - Real World Outcomes;2024-05-10

4. Treatment Attrition, Concomitant Pharmaceutical Use, Temporal Claims-Based Utilization, and Real-World Characteristics Among Esketamine New Initiators in the United States, 2019-2022;2024-04-23